Rapporteur: committee member who leads an EMA assessment

A rapporteur is the EMA committee member appointed to lead the scientific assessment of an application; a co-rapporteur writes a second, separate report.

Also known as: co-rapporteur, CHMP rapporteur, PRAC rapporteur

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 62(1) of Regulation (EC) No 726/2004
Appointed by
The CHMP, the CAT for advanced therapies, the PRAC for risk management
When
Requested seven months before submission; appointment takes one to two months
Applicant's choice
None: preferences are not considered

How it works

Article 62(1) of Regulation (EC) No 726/2004 requires an EMA committee that has to evaluate a medicine to appoint one of its members as rapporteur, taking into account the expertise available in that member's country, and allows it to appoint a second member as co-rapporteur. For a full centralised application the CHMP appoints a rapporteur and a co-rapporteur, and the PRAC appoints its own for the risk management plan. For advanced therapies the rapporteurs come from the Committee for Advanced Therapies, supported by two CHMP coordinators. A generic application usually has a rapporteur only, and a co-rapporteur for a hybrid is decided case by case. Each rapporteur leads an assessment team drawn from a national agency, and the committee appoints peer reviewers from among its other members at the same time.

The applicant asks for the appointment in a letter of intent, submitted through EMA's IRIS platform about seven months before the intended submission date. EMA starts the appointment no earlier than that, the process generally takes one to two months, and the committee decides on objective criteria: the applicant's preferences are not considered. EMA charges a fee for pre-submission requests. The declared submission date matters, because the assessment teams plan around it. A delay of more than 60 days against the declared date carries an additional fee, and a slip of several months can mean the rapporteurs have to be reappointed.

During the assessment the rapporteur and co-rapporteur each send an assessment report to the committee at about Day 80. EMA forwards the reports to the applicant for information, but they set out preliminary conclusions and are not the position of the CHMP. After peer review and comments from other members, the reports are consolidated into the list of questions adopted at Day 120. The rapporteurs then assess the responses jointly, can meet the applicant to clarify the questions, and prepare the opinion. If the applicant asks for re-examination of an opinion, the committee must appoint a different rapporteur and, where necessary, a different co-rapporteur.

The role has equivalents elsewhere. In a referral the committee also appoints a rapporteur under Article 32(2) of Directive 2001/83/EC, and in decentralised and mutual recognition procedures the reference member state does the same job for the Member States concerned.

What goes wrong

Declaring an optimistic submission date in the letter of intent and then missing it; contacting the rapporteurs between the start of the procedure and Day 120, when applicants are asked to refrain; reading the Day 80 reports as the committee's view and preparing answers to points that never reach the list of questions; addressing one rapporteur's concerns and neglecting the other's where the two reports diverge; and not using the clarification meeting after the list of questions to test the response strategy.

Timing

  1. 7 months before submission

    Applicant submits the letter of intent through IRIS.

  2. 1 to 2 months later

    CHMP appoints the rapporteur, co-rapporteur and peer reviewers.

  3. Day 80

    Rapporteurs' assessment reports go to the CHMP and, for information, to the applicant.

  4. Day 120

    CHMP adopts the list of questions built from those reports.

  5. Day 157

    Joint assessment report on the applicant's responses.

  6. By Day 210

    CHMP adopts its opinion.

The letter of intent is submitted about seven months before the intended submission, to one of EMA's monthly deadlines, and the rapporteurs are appointed at a CHMP plenary one to two months later. In the standard timetable their assessment reports reach the committee by about Day 80, the list of questions is adopted at Day 120, the joint assessment of the responses is circulated at Day 157 and the opinion is adopted by Day 210. For a re-examination, new rapporteurs are appointed as soon as the applicant gives notice, and the committee concludes within 60 days of receiving the grounds.

What teams do with it in Regunaut

One job in the platform that turn on Rapporteur, each part of a wider workflow.

Rapporteur: common questions

Can an applicant choose its rapporteur?

No. EMA's guidance states that the applicant's proposals and preferences are not considered. The CHMP appoints the rapporteur and co-rapporteur on objective criteria, so as to use the best available expertise in the EEA. The applicant's part is to send the letter of intent about seven months before submission and keep the declared submission date realistic.

What is the difference between a rapporteur and a co-rapporteur?

Both are committee members who lead separate assessment teams and write their own assessment reports on the same application, which gives the CHMP two independent readings of the dossier. Their reports are peer reviewed and merged into one list of questions, and from the response stage onwards they produce joint assessment reports.

Do generic applications have a co-rapporteur?

Usually not. For a generic application in the centralised procedure EMA appoints a CHMP rapporteur and a PRAC rapporteur, and normally no co-rapporteur. For a hybrid application a co-rapporteur is considered case by case. Since March 2025 EMA has also been piloting a single CHMP rapporteur for certain biosimilar applications.

Sources

  1. EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use
  2. European Medicines Agency: Pre-authorisation guidance for users of the centralised procedure
  3. European Medicines Agency: The evaluation of medicines, step-by-step

Put your Rapporteur question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.